G2TT
来源类型Working Paper
规范类型报告
DOI10.3386/w16014
来源IDWorking Paper 16014
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
Mark Trusheim; Murray L. Aitken; Ernst R. Berndt
发表日期2010-05-20
出版年2010
语种英语
摘要Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile. Employing a data base encompassing all 96 biologics and 212 small molecules newly launched in the U.S. between 1998Q1 and 2008Q4, we compare their downstream clinical and commercial characteristics -- therapeutic class concentration, launch delays following approval, Orphan Drug and priority review status, supplemental indications, black box warning and safety record, and pricing and revenue growth during the product life cycle. We conclude that the market dynamics of biologics differ substantially from those of small molecules, although therapeutic class composition plays a major role.
主题Microeconomics ; Households and Firms ; Health, Education, and Welfare ; Health ; Industrial Organization ; Industry Studies
URLhttps://www.nber.org/papers/w16014
来源智库National Bureau of Economic Research (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/573688
推荐引用方式
GB/T 7714
Mark Trusheim,Murray L. Aitken,Ernst R. Berndt. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. 2010.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
w16014.pdf(1358KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mark Trusheim]的文章
[Murray L. Aitken]的文章
[Ernst R. Berndt]的文章
百度学术
百度学术中相似的文章
[Mark Trusheim]的文章
[Murray L. Aitken]的文章
[Ernst R. Berndt]的文章
必应学术
必应学术中相似的文章
[Mark Trusheim]的文章
[Murray L. Aitken]的文章
[Ernst R. Berndt]的文章
相关权益政策
暂无数据
收藏/分享
文件名: w16014.pdf
格式: Adobe PDF
此文件暂不支持浏览

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。